JO3402B1 - ملح جديد للأبيكسينوستات ,شكل بلوري مرافق , طريقة تحضيرها والتركيبات الصيدلانية التي تحتوي عليها - Google Patents

ملح جديد للأبيكسينوستات ,شكل بلوري مرافق , طريقة تحضيرها والتركيبات الصيدلانية التي تحتوي عليها

Info

Publication number
JO3402B1
JO3402B1 JOP/2014/0040A JOP20140040A JO3402B1 JO 3402 B1 JO3402 B1 JO 3402B1 JO P20140040 A JOP20140040 A JO P20140040A JO 3402 B1 JO3402 B1 JO 3402B1
Authority
JO
Jordan
Prior art keywords
crystalline form
abexinostat
salt
novel
preparation
Prior art date
Application number
JOP/2014/0040A
Other languages
English (en)
Inventor
Pimont-Garro Anne
Letellier Philippe
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48521256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3402(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Application granted granted Critical
Publication of JO3402B1 publication Critical patent/JO3402B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

توسيليت أبيكسينوستات من الصيغة (<span dir="LTR">II</span>): وشكله البلوري <span dir="LTR">I</span> يمتاز رسم بياني حيود مسحوق أشعة اكس، ومطيافية رامان ومطيافية الرنين النووري المغناطيسي 13<span dir="LTR">C</span> الحالة الصلبة. <span dir="RTL">أدوية</span><br />
JOP/2014/0040A 2013-03-04 2014-02-18 ملح جديد للأبيكسينوستات ,شكل بلوري مرافق , طريقة تحضيرها والتركيبات الصيدلانية التي تحتوي عليها JO3402B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772191P 2013-03-04 2013-03-04
FR1351898A FR3002733B1 (fr) 2013-03-04 2013-03-04 Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
JO3402B1 true JO3402B1 (ar) 2019-10-20

Family

ID=48521256

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0040A JO3402B1 (ar) 2013-03-04 2014-02-18 ملح جديد للأبيكسينوستات ,شكل بلوري مرافق , طريقة تحضيرها والتركيبات الصيدلانية التي تحتوي عليها

Country Status (39)

Country Link
US (3) US9115108B2 (ar)
EP (2) EP3252044A1 (ar)
JP (2) JP6449177B2 (ar)
CN (2) CN105263917B (ar)
AR (1) AR094935A1 (ar)
AU (2) AU2014224456B2 (ar)
BR (1) BR112015021443A2 (ar)
CA (1) CA2903369C (ar)
CL (1) CL2015002488A1 (ar)
CR (1) CR20150456A (ar)
CY (1) CY1119147T1 (ar)
DK (1) DK2964622T3 (ar)
DO (1) DOP2015000215A (ar)
EA (2) EA030689B1 (ar)
ES (1) ES2632471T3 (ar)
FR (1) FR3002733B1 (ar)
GE (1) GEP201706760B (ar)
HK (1) HK1220965A1 (ar)
HR (1) HRP20171041T1 (ar)
HU (1) HUE035299T2 (ar)
IL (1) IL241038B (ar)
JO (1) JO3402B1 (ar)
LT (1) LT2964622T (ar)
MA (1) MA38423B1 (ar)
ME (1) ME02814B (ar)
MX (1) MX355436B (ar)
MY (1) MY192027A (ar)
NI (1) NI201500122A (ar)
PE (1) PE20151591A1 (ar)
PL (1) PL2964622T3 (ar)
PT (1) PT2964622T (ar)
RS (1) RS56224B1 (ar)
SG (1) SG11201506952YA (ar)
SI (1) SI2964622T1 (ar)
TN (1) TN2015000367A1 (ar)
TW (1) TWI506023B (ar)
UA (1) UA118550C2 (ar)
UY (1) UY35356A (ar)
WO (1) WO2014135776A1 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113343A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AP2015008381A0 (en) 2012-11-02 2015-04-30 Pfizer Bruton's tyrosine kinase inhibitors
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
AU2015311905B2 (en) * 2014-09-03 2020-03-05 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl)-N-{2-(4-(hydroxycarbamoyl) phenoxy)ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
FR3025196B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3025197B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2022261401A1 (en) 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
AU2004230889B2 (en) * 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PT2964622T (pt) 2017-07-13
CL2015002488A1 (es) 2016-03-11
BR112015021443A2 (pt) 2017-07-18
US20170313671A1 (en) 2017-11-02
GEP201706760B (en) 2017-10-25
HUE035299T2 (en) 2018-05-02
EA201891023A1 (ru) 2019-03-29
AU2014224456A8 (en) 2015-10-22
MY192027A (en) 2022-07-23
CN105263917B (zh) 2018-11-20
EP3252044A1 (fr) 2017-12-06
TN2015000367A1 (fr) 2017-01-03
US9115108B2 (en) 2015-08-25
EA030689B1 (ru) 2018-09-28
WO2014135776A1 (fr) 2014-09-12
MA38423A1 (fr) 2017-02-28
AU2014224456A1 (en) 2015-10-08
JP6449177B2 (ja) 2019-01-09
DOP2015000215A (es) 2015-09-30
JP2016510735A (ja) 2016-04-11
US10150748B2 (en) 2018-12-11
UY35356A (es) 2014-09-30
PL2964622T3 (pl) 2017-10-31
NI201500122A (es) 2018-10-18
FR3002733B1 (fr) 2015-08-14
US20150315167A1 (en) 2015-11-05
MX2015011566A (es) 2016-06-24
CN109734690B (zh) 2023-08-11
HK1220965A1 (zh) 2017-05-19
AU2018202881A1 (en) 2018-05-17
RS56224B1 (sr) 2017-11-30
CR20150456A (es) 2015-10-21
EP2964622B1 (fr) 2017-04-19
AU2014224456B2 (en) 2018-01-25
MA38423B1 (fr) 2017-10-31
DK2964622T3 (en) 2017-07-31
CN105263917A (zh) 2016-01-20
EA039113B1 (ru) 2021-12-06
CY1119147T1 (el) 2018-02-14
TW201434822A (zh) 2014-09-16
ES2632471T3 (es) 2017-09-13
AU2018202881B2 (en) 2020-02-27
TWI506023B (zh) 2015-11-01
CN109734690A (zh) 2019-05-10
MX355436B (es) 2018-04-18
AR094935A1 (es) 2015-09-09
JP6720280B2 (ja) 2020-07-08
LT2964622T (lt) 2017-08-10
SG11201506952YA (en) 2015-10-29
IL241038A0 (en) 2015-11-30
EP2964622A1 (fr) 2016-01-13
FR3002733A1 (fr) 2014-09-05
US20140249215A1 (en) 2014-09-04
IL241038B (en) 2019-09-26
HRP20171041T1 (hr) 2017-10-06
CA2903369A1 (en) 2014-09-12
PE20151591A1 (es) 2015-11-06
NZ712380A (en) 2020-10-30
EA201591530A1 (ru) 2016-01-29
ME02814B (me) 2018-01-20
SI2964622T1 (sl) 2017-10-30
CA2903369C (en) 2021-06-08
UA118550C2 (uk) 2019-02-11
JP2019069955A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
JO3402B1 (ar) ملح جديد للأبيكسينوستات ,شكل بلوري مرافق , طريقة تحضيرها والتركيبات الصيدلانية التي تحتوي عليها
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
JO3648B1 (ar) عملية لتحضير (4s)- 4-(4- سيانو-2- ميثوكسي فينيل)-5-إيثوكسي-8،2- داي ميثيل-4،1- دايهيدرو-6،1- نفثيريدين-3- كربوكساميد وتنقيته للاستخدام كمقوم نشط دوائيا
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2015000281A1 (fr) Lactames condenses aryliques et heteroaryliques
GEP201706619B (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical composition containing them
JO3275B1 (ar) مشتقات بيرول جديدة وطريقة لتحضيرها وتركيبات صيدلانية التي تحتوي عليها
JO3160B1 (ar) مشتقات الفوسفات الجديدة, طريقة تحضيرها والتركيبات الدوائية التي تحتوي عليها
MX2012013274A (es) Novedosos derivados de la pirimidina.
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
CY1121484T1 (el) Μορφες αλατος και κρυσταλλου ενος αναστολεα plk-4
JO3457B1 (ar) مركبات الايزو اندولين أو الايزو كوينولين الجديدة وعملية لتحضيرها والتركيبات الدوائية التي تحتوي عليها
PH12019500467A1 (en) Benzo-fused heterocyclic derivatives useful agonists of gpr120
PH12015502632A1 (en) Cxcr7 receptor modulators
JO3610B1 (ar) مشتقات كربوكساميد
MX2015007116A (es) Nuevos derivados de 1,4-ditiina sustituida y su uso como fungicidas.
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2013000013A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen.
MX2016006507A (es) Nuevos compuestos.
EP2644688A3 (en) Novel pyrimidine derivatives and their use in perfume compositions
RU2012118848A (ru) Средство для стимуляции роста волос
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
TN2011000518A1 (en) Fused imidazole carboxamides as trpv3 modulators
TH151188A (th) รูปผลึกเดลตาของเกลืออาร์จินีน (arginine) ของเพอรินโดพริล (perindopril), กระบวนการสำหรับการเตรียมสารดังกล่าว และองค์ประกอบทางเภสัชกรรมที่มีสารดังกล่าว